Phase II preoperative pembrolizumab for MSI high or MSS/PD-L1 gastric cancer followed by surgery and adjuvant therapy with pembrolizumab (NCT03257163): Results of a multicenter study

被引：0
|
作者：
Kennedy, Timothy
Shah, Mihir Maheshkumar
Kabarriti, Rafi
Boland, Patrick M.
In, Haejin
Chen, Chunxia
Szabo, Stephen M.
Hochster, Howard S.
Moore, Dirk F.
Jabbour, Salma K.
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] Emory Univ, Winship Canc Inst, Dept Surg, Div Surg Oncol, Atlanta, GA USA
[3] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA
[4] Rutgers Sch Publ Hlth, New Brunswick, NJ USA
[5] Emory Univ, Duluth, GA USA
[6] Rutgers Canc Inst, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.441
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：441 / 441
页数：1
相关论文
共 50 条
  • [1] Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163).
    Kennedy, Timothy
    Shah, Mihir Maheshkumar
    In, Haejin
    Chuy, Jennifer W.
    Moore, Dirk F.
    Kooby, David A.
    Kabarriti, Rafi
    Szabo, Stephen M.
    Hochster, Howard S.
    Jabbour, Salma K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial
    Kennedy, Timothy
    Shah, Mihir Maheshkumar
    Acuna-Villaorduna, Ana
    Chen, Chunxia
    Boland, Patrick M.
    Kooby, David A.
    In, Haejin
    Szabo, Stephen M.
    Kabarriti, Rafi
    Dutta, Sunil W.
    Hochster, Howard S.
    Moore, Dirk F.
    Jabbour, Salma K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
    Christenson, E. S.
    Kazmi, S.
    Mahadevan, D.
    Sohal, D.
    Manda, S.
    Martz, A.
    Kordahi, S.
    Zika, M.
    Kothari, P.
    Kahan, S.
    Barbu, E. A.
    Morawski, A.
    Flies, D.
    Langermann, S. A. R.
    Chisamore, M.
    Fu, S.
    Wadlow, R.
    Guha, U.
    Myint, H.
    Le, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S468 - S468
  • [4] Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
    Marmarelis, M. E.
    Mathew, D.
    Bauml, J. M.
    Hwang, W. -T.
    Zhang, J.
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Zhang, N.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A. J.
    Wherry, E. J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S122 - S123
  • [5] Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up
    Marmarelis, M. E.
    Cantor, D. J.
    Mathew, D.
    McWilliams, T.
    Bauml, J.
    Hwang, W-T
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A.
    Wherry, J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S20 - S20
  • [6] Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial
    Shitara, K.
    Golan, T.
    Mileham, K.
    Voskoboynik, M.
    Rha, S.
    Gutierrez, M.
    Perets, R.
    Taylor, S.
    Chen, D.
    Keenan, T.
    Rajasagi, M.
    Healy, J.
    Shoji, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S240 - S240
  • [7] Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.
    Varga, Andrea
    Piha-Paul, Sarina Anne
    Ott, Patrick Alexander
    Mehnert, Janice M.
    Berton-Rigaud, Dominique
    Johnson, Elizabeth A.
    Cheng, Jonathan D.
    Yuan, Sammy
    Rubin, Eric H.
    Matei, Daniela E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study
    Ledermann, J. A.
    Shapira-Frommer, R.
    Santin, A.
    Lisyanskaya, A. S.
    Pignata, S.
    Vergote, I.
    Raspagliesi, F.
    Sonke, G. S.
    Birrer, M. J.
    Provencher, D. M.
    Sehouli, J.
    Colombo, N.
    Gonzalez-Martin, A.
    Oaknin, A.
    Ottevanger, P. B.
    Rudaitis, V.
    Cristescu, R.
    Kobie, J.
    Ruman, J.
    Matulonis, U. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 728 - 728
  • [9] Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Hamai, Kosuke
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    THORACIC CANCER, 2022, 13 (11) : 1611 - 1618
  • [10] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
    Amin, Asim
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Medina, Theresa Michelle
    Conry, Robert Martin
    Lao, Christopher D.
    Daniels, Gregory A.
    Reddy, Sunil A.
    Andtbacka, Robert Hans Ingemar
    Barve, Minal A.
    Shaheen, Montaser F.
    Tueting, Thomas
    Chisamore, Michael Jon
    Schmidt, Emmett V.
    Candia, Albert
    Obiozor, Cynthia Chinedu
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345